Advisory Alpha LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 63.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,155 shares of the medical research company's stock after selling 2,034 shares during the quarter. Advisory Alpha LLC's holdings in IQVIA were worth $204,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of IQV. GKV Capital Management Co. Inc. bought a new stake in IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the fourth quarter worth $44,000. Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the fourth quarter valued at $60,000. Finally, Thematics Asset Management bought a new stake in shares of IQVIA in the fourth quarter valued at $76,000. 89.62% of the stock is currently owned by institutional investors.
IQVIA Price Performance
IQVIA stock traded down $0.68 during midday trading on Thursday, hitting $147.22. 3,264,210 shares of the company's stock were exchanged, compared to its average volume of 1,592,360. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The stock has a 50-day moving average price of $148.07 and a two-hundred day moving average price of $179.40. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $25.47 billion, a P/E ratio of 19.63, a PEG ratio of 1.99 and a beta of 1.28.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same period in the prior year, the business earned $2.54 EPS. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Wall Street Analysts Forecast Growth
IQV has been the topic of several research reports. Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Truist Financial lowered their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $226.32.
Check Out Our Latest Research Report on IQVIA
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
